ESS MAIL CERTIFICATE 11-07-03

Label No. EV 340064356 UC I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 by "Express Mail Post Office to

Addressee" service.

Name (Print)

Customer No.: 07278

Docket No.: 05432/100J951-US4

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Connie SANCHEZ et al.

Serial No.:

10/644,143

Confirmation No.: Not Yet Assigned

Art Unit: Not Yet Assigned

Filed:

August 20, 2003

Examiner: Not Yet Assigned

For:

TREATMENT OF NEUROTIC DISORDERS

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

In order to comply with 37 CFR 1.97 and 1.98, attached hereto is a copy of form PTO/SB/08. The patents and publications cited in the attached form PTO/SB/08 are not supplied pursuant to 37 CFR 1.98(d) because they were previously cited by or submitted to the Office in the parent application (U.S. Serial No. 10/021,126, filed December 12, 2001).

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing form PTO/SB/08 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied

with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

This submission is filed within three months of the filing date of this application.

The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

It is believed that no fee is due. However, if the Commissioner determines that a fee is due, the Commissioner is hereby authorized to charge Deposit Account No. 04-0100 for any deficiency.

Early and favorable consideration is earnestly solicited.

Dated: November 7, 2003

Jay P. Lessler

Registration No. 41,151 Attorney for Applicant(s)

Respectfully submitted,

DARBY & DARBY Post Office Box 5257 New York, NY 10150-5257 (212) 527-7700



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	stitute for form 1449A/B/P	то		Complete if Known		
				Application Number	10/644,143	
l IN	<b>IFORMATIO</b>	N DI	SCLOSURE	Filing Date	Concurrently Herewith	
S	TATEMENT	BY /	APPLICANT	First Named Inventor	Connie Sanchez	
				Art Unit	N/A	
	(Use as many sl	neets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	05432/100J951-US4	

	U.S. PATENT DOCUMENTS							
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where			
Initials*	No.1	Number-Kind Code <sup>2</sup> ( if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear			
	AA	US-6,469,064 B2	10-22-2002	Druzgala				
	AB	US-6,333,357 B1	12-25-2001	Eig				
	AC	US-6,159,971	12-12-2000	Berg et al.				
	AD	US-6,147,072	11-14-2000	Bymaster et al.				
	AE	US-6,069,177	05-30-2000	Carlier et al.				
	AF	US-5,962,514	10-05-1999	Evenden et al.				
	AG	US-5,958,429	09-28-1999	Wong				
	AH	US-5,788,986	08-04-1998	Dodman				
	ΑI	US-5,648,396	07-15-1997	Young et al.				
	AJ	US-5,296,507	03-22-1994	Tanaka et al.				
	AK	US-5,114,976	05-19-1992	Norden				
	AL	US-4,962,128	10-09-1990	Doogen et al.				
	AM	US-4,943,590	07-24-1990	Boegesoe et al.				
	AN	US-4,902,710	02-20-1990	Foster et al.				
	AO	US-4,650,884	01-23-1979	Bogeso et al.				
	AP	US-4.136,193	01-23-1979	Bogeso et al.				
	AQ	US-3,467,675	09-16-1969	Peterson et al.				

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>			
	BA	WO-00/15220	03-23-2000	Astra Aktiebolag	or relevant rigures Appear				
	ВВ	WO-01/54681 A2	08-02-2001	Massachusetts Institute of Technology					
	ВС	WO-00/15219	03-23-2000	Astra Aktiebolag					
	BD	WO-00/03701	01-27-2000	Massachusetts Institute of Technology					
	BE	WO-00/02551	01-20-2000	NPS Pharmaceutical, Inc.					
	BF	EP-0759299	02-26-1997	Eli Lilly and Company					
	BG	EP-0714663 A2	06-05-1996	Eli Lilly and Company					
	ВН	WO-93/09769	05-27-1993	Sepracor, Inc.					
	ВІ	WO-00/34263	06-15-2000	H Lundbeck A/S					
	BJ	WO-92/18005	10-29-1992	National Institutes of Health					

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

{W:\054   Date   Considered			
`	{W:\054	Date	
	32\100	Considered	



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known		
				Application Number	10/644,143	
l in	<b>IFORMATION</b>	I DI	SCLOSURE	Filing Date	Concurrently Herewith	
l s	STATEMENT BY APPLICANT			First Named Inventor	Connie Sanchez	
				Art Unit	N/A	
	(Use as many she	eets as	s necessary)	Examiner Name	Not Yet Assigned	
Sheet	2	of	2	Attorney Docket Number	05432/100J951-US4	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	CA	A.F. Joubert et al., "Citalopram and Anixety Disorders," Rev. Contemp. Pharmacither 10: 79-131 (1999)	
	СВ	Ulla M. Lepola et al., "A Controlled Perspective, 1 -Year Trial of Citalopram in the Treatment of Panic Disorder," J. CLin. Psychiatry 59, 10: 528-534 (1998)	
	CC	H. Koponen et al., "Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study," Acta Psychiatrica Scandinavica 96:343-346 (1997)	
	CD	Dan J. Stein et al., "Use of serotonin selective reuptake inhibitor citalopram in obsessive-compulsive disorder," Journal of Serotonin Research 1: 29-33 (1996)	
	CE	Bigler, Allan et al., "Quantitative Struacture-activity Relationships in a Series of Selective 5-HT uptake inhibitors," Eur. J. Med. Chem. 3:289-295 (1997)	
	CF	Soraya Seedat et al., "Open Trial of Citalopram in adults with post-tramatic stress disorder," International Journal of Neuropsychopharmacology 3: 135-140 (2000)	
	CG	Ihoko Muraki et al., "Effect of subchronic lithium carbonate treatment on anxiolytic-like effect of citalopram and MKC-242 in conditioned fear stress in the rat," European Journal of Pharmacology 383:223-229 (1999)	
	СН	Jennifer Y. Tan et al, "Citalopram in the Treatment of Depression and Other Potential Uses in Psychiatry," Pharmacotherapy 19, 6: 675-689 (1999)	
	CI	Mario Amore et al., "Short-term and Long-term evaluation of Selective Serotonin Reuptake Inhibitors in the Treatment of Panic Disorder: Florxetine vs. Citalopram," Hum. Psychopharmacol. Clin. Exp. 14: 435-440 (1999)	
	CJ	Emanuela Mundo, M.D. et al., "Efficacy of Fluvoxamine, Paroxetine, and Citalopram in the Treatment of Obsessive-Compulsive Disorder: A Single-Blind Study," Journal of Clinical Psychopharmacology 17, 4: 267-271 (August 1997)	
	СК	Zoltan Rihmer, "Successful treatment of salbutamol-induced panic disorder with citalopram," European Neuropsychopharmacology 7:241-242 (1997)	
	CL	Takeshi Inoue et al., "Effect of italopram, a selective serotonin reuptake inhibitor, on the acquisition of conditioned freezing," European Journal of Pharmacology 311: 1-6 (1996)	
	СМ	U. Lepola et al., "Citalopram in the Treatment of Early-onset Panic Disorder and School Phobia," Pharmacopsychiatry 29: 30-32 (January 1996)	
	CN	J. Hyttel et al., "The Pharmacology of Citalopram," Rev. Contemp. Pharmacother. 6: 271-285 (1995)	
	со	American Psychiatric Associations, "DSM-IV" (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition): 393-444 (1994)	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

{W:\054	Date
32\100.1	Considered

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.